Mabion (WAR:MAB) Moat Score: 0/10 (As of Jul. 04, 2026)


WAR:MAB Mabion SA WAR:MAB
29 GF Score
Price zł7.28
GF Value zł2.09
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Mabion Moat Score?

Mabion has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Mabion has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Mabion might have No Moat - No discernible moat.

Mabion  (WAR:MAB) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Mabion Moat Score Related Terms

WAR:MAB
29GF Score
Mabion SA WAR:MAB
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Mabion (WAR:MAB) Overvalued in 2026?

Based on GuruFocus' analysis, Mabion stock appears to be overvalued. The current stock price of zł7.28 is trading 248.3% above its estimated GF Value™ of zł2.09. GuruFocus considers Mabion to be Significantly Overvalued.

Key valuation signals for WAR:MAB:

  • Moat Score: 0
  • GF Value™: zł2.09 vs. price of zł7.28 (248.3% above fair value)
  • GF Score™: 29/100 with 4 warning signs

No single metric tells the full story. See the WAR:MAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Mabion Business Description

Other Exchanges 272:Germany
Address ul. Gen. Mariana Langiewicza 60, Konstantynow Lodzki, POL, 95-050
Mabion SA is a Polish biotechnology company focused on developing and launching modern biotechnology drugs based on monoclonal antibody technology. The drugs developed by the company are targeted treatments, characterized by the drug's ability to recognize the factor causing cancer and interact with this factor only. The company is working on the development of its main priority drug, referred to as the MabionCD20 drug. The therapeutic uses of MabionCD20 are for Non-Hodgkin's lymphoma, Leukemia, and Rheumatoid Arthritis.
29GF Score

Get the complete analysis for WAR:MAB

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł7.28
Price
zł2.09
GF Value